Practical guidance for licensing teams and asset owners.

Therapeutic candidates, platform technologies, diagnostics, delivery systems, biomarkers, and other credible life-sciences opportunities can be structured for review.

Yes. Early programs can be presented with stage-appropriate evidence, limitations, ownership context, and controlled disclosure settings.

Public, registered, approved, NDA-restricted, and data-room-only layers are kept distinct, with organization-aware access intended to be enforced on the server and in database rules.

No. It is designed as a structured licensing-intelligence and controlled collaboration platform, not an open transactional marketplace.

The architecture anticipates configurable questionnaires, scoring methods, approval gates, and organization-specific decision criteria.

No. It organizes evidence and workflow. Qualified scientific, clinical, regulatory, legal, and commercial reviewers remain accountable.

Only as uncertain, illustrative decision support with assumptions, confidence, missing data, model version, and human-review status.

Yes. Selected opportunities can be compared using consistent scientific, development, evidence, rights, and strategic-fit dimensions.

Yes. Rights, territories, exclusions, and transaction preferences can be represented separately.

Yes. The intended workflow requires explicit approval before restricted or data-room information is made available.

Organizations submit a structured rationale, rights and territories of interest, requested information, and preferred next step for owner review.

The architecture includes future connectors for internal search, evidence, identity, analytics, and audit systems; no paid connector is enabled in this demonstration.